

Hiroyuki Seimiya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8767549/publications.pdf>

Version: 2024-02-01

99
papers

4,635
citations

126907

33
h-index

102487

66
g-index

101
all docs

101
docs citations

101
times ranked

6790
citing authors

#	ARTICLE	IF	CITATIONS
1	Generation of Induced Pluripotent Stem Cells from Human Terminally Differentiated Circulating T Cells. <i>Cell Stem Cell</i> , 2010, 7, 11-14.	11.1	547
2	HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. <i>Nature</i> , 2012, 489, 313-317.	27.8	488
3	ATP Citrate Lyase: Activation and Therapeutic Implications in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2008, 68, 8547-8554.	0.9	326
4	Telomerase Inhibition, Telomere Shortening, and Senescence of Cancer Cells by Tea Catechins. <i>Biochemical and Biophysical Research Communications</i> , 1998, 249, 391-396.	2.1	226
5	c-Jun NH2-terminal Kinase-mediated Activation of Interleukin-1 β Converting Enzyme/CED-3-like Protease during Anticancer Drug-induced Apoptosis. <i>Journal of Biological Chemistry</i> , 1997, 272, 4631-4636.	3.4	182
6	ASK1 mediates apoptotic cell death induced by genotoxic stress. <i>Oncogene</i> , 1999, 18, 173-180.	5.9	169
7	Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. <i>Cancer Cell</i> , 2005, 7, 25-37.	16.8	160
8	The Telomeric Poly(ADP-ribose) Polymerase, Tankyrase 1, Contains Multiple Binding Sites for Telomeric Repeat Binding Factor 1 (TRF1) and a Novel Acceptor, 182-kDa Tankyrase-binding Protein (TAB182). <i>Journal of Biological Chemistry</i> , 2002, 277, 14116-14126.	3.4	129
9	Telomestatin Impairs Glioma Stem Cell Survival and Growth through the Disruption of Telomeric G-Quadruplex and Inhibition of the Proto-oncogene, <i>c-Myb</i> . <i>Clinical Cancer Research</i> , 2012, 18, 1268-1280.	7.0	105
10	Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 13844-13849.	7.1	102
11	Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 657-65.	4.1	99
12	Revisiting Telomere Shortening in Cancer. <i>Cells</i> , 2019, 8, 107.	4.1	98
13	Hypoxia Up-Regulates Telomerase Activity via Mitogen-Activated Protein Kinase Signaling in Human Solid Tumor Cells. <i>Biochemical and Biophysical Research Communications</i> , 1999, 260, 365-370.	2.1	90
14	The telomeric PARP, tankyrases, as targets for cancer therapy. <i>British Journal of Cancer</i> , 2006, 94, 341-345.	6.4	88
15	Functional Subdomain in the Ankyrin Domain of Tankyrase 1 Required for Poly(ADP-Ribosyl)ation of TRF1 and Telomere Elongation. <i>Molecular and Cellular Biology</i> , 2004, 24, 1944-1955.	2.3	83
16	<i>APC</i> Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 752-762.	4.1	67
17	Acyl-CoA synthetase as a cancer survival factor: its inhibition enhances the efficacy of etoposide. <i>Cancer Science</i> , 2009, 100, 1556-1562.	3.9	62
18	Telomeric repeat-containing RNA/G-quadruplex-forming sequences cause genome-wide alteration of gene expression in human cancer cells in vivo. <i>Nucleic Acids Research</i> , 2015, 43, 2022-2032.	14.5	62

#	ARTICLE	IF	CITATIONS
19	Visualization of G-quadruplexes by using a BODIPY-labeled macrocyclic heptaioxazole. <i>Organic and Biomolecular Chemistry</i> , 2010, 8, 2749.	2.8	61
20	<scp>RK</scp>â€287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. <i>Cancer Science</i> , 2018, 109, 4003-4014.	3.9	60
21	TRIB1 Supports Prostate Tumorigenesis and Tumor-Propagating Cell Survival by Regulation of Endoplasmic Reticulum Chaperone Expression. <i>Cancer Research</i> , 2014, 74, 4888-4897.	0.9	53
22	Reprogramming Suppresses Premature Senescence Phenotypes of Werner Syndrome Cells and Maintains Chromosomal Stability over Long-Term Culture. <i>PLoS ONE</i> , 2014, 9, e112900.	2.5	52
23	Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells. <i>International Journal of Cancer</i> , 2014, 135, 37-47.	5.1	52
24	G-quadruplex in cancer biology and drug discovery. <i>Biochemical and Biophysical Research Communications</i> , 2020, 531, 45-50.	2.1	48
25	Telomere Length Influences Cancer Cell Differentiation <i><i>In Vivo</i></i> . <i>Molecular and Cellular Biology</i> , 2013, 33, 2988-2995.	2.3	45
26	Inhibition of ATP Citrate Lyase Induces an Anticancer Effect via Reactive Oxygen Species. <i>American Journal of Pathology</i> , 2013, 182, 1800-1810.	3.8	44
27	Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 34811-34823.	1.8	43
28	Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3407-3427.	6.4	43
29	Pim-1 Negatively Regulates the Activity of PTP-U2S Phosphatase and Influences Terminal Differentiation and Apoptosis of Monoblastoid Leukemia Cells. <i>Archives of Biochemistry and Biophysics</i> , 2001, 390, 9-18.	3.0	41
30	Pharmacological Targeting of Constitutively Active Truncated Androgen Receptor by Nigericin and Suppression of Hormone-Refractory Prostate Cancer Cell Growth. <i>Molecular Pharmacology</i> , 2010, 78, 846-854.	2.3	41
31	A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 2010, 394, 569-573.	2.1	41
32	Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole. <i>Scientific Reports</i> , 2017, 7, 3605.	3.3	40
33	Pericentromeric noncoding RNA changes DNA binding of CTCF and inflammatory gene expression in senescence and cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	38
34	Role of Insulin-Like Growth Factor Binding Protein 2 in Lung Adenocarcinoma. <i>American Journal of Pathology</i> , 2010, 176, 1756-1766.	3.8	36
35	ALDH1A3â€mTOR axis as a therapeutic target for anticancer drugâ€tolerant persister cells in gastric cancer. <i>Cancer Science</i> , 2020, 111, 962-973.	3.9	36
36	Tankyrase-Binding Protein TNKS1BP1 Regulates Actin Cytoskeleton Rearrangement and Cancer Cell Invasion. <i>Cancer Research</i> , 2017, 77, 2328-2338.	0.9	33

#	ARTICLE	IF	CITATIONS
37	Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells. <i>Oncogene</i> , 1999, 18, 1277-1283.	5.9	30
38	Evaluation of the Interaction between Long Telomeric DNA and Macrocyclic Hexaoxazole (6OTD) Dimer of a G-quadruplex Ligand. <i>Molecules</i> , 2013, 18, 4328-4341.	3.8	30
39	G-quadruplex ligand-induced DNA damage response coupled with telomere dysfunction and replication stress in glioma stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 471, 75-81.	2.1	30
40	TRF1 Ensures the Centromeric Function of Aurora-B and Proper Chromosome Segregation. <i>Molecular and Cellular Biology</i> , 2014, 34, 2464-2478.	2.3	29
41	Cross-species difference in telomeric function of tankyrase 1. <i>Cancer Science</i> , 2007, 98, 850-857.	3.9	28
42	Design and Synthesis of a Berberine Dimer: A Fluorescent Ligand with High Affinity towards G-quadruplexes. <i>Chemistry - A European Journal</i> , 2015, 21, 14519-14528.	3.3	28
43	Crossroads of telomere biology and anticancer drug discovery. <i>Cancer Science</i> , 2020, 111, 3089-3099.	3.9	28
44	HnRNP A3 binds to and protects mammalian telomeric repeats in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2007, 358, 608-614.	2.1	27
45	TRF1 Mediates Mitotic Abnormalities Induced by Aurora-A Overexpression. <i>Cancer Research</i> , 2010, 70, 2041-2052.	0.9	26
46	A Caged Ligand for a Telomeric G-quadruplex. <i>ChemBioChem</i> , 2012, 13, 774-777.	2.6	25
47	Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4183-4204.	6.4	25
48	Senescence from glioma stem cell differentiation promotes tumor growth. <i>Biochemical and Biophysical Research Communications</i> , 2016, 470, 275-281.	2.1	24
49	M-CSF gene transduction in multidrug-resistant human cancer cells to enhance anti-P-glycoprotein antibody-dependent macrophage-mediated cytotoxicity. <i>International Journal of Cancer</i> , 1993, 54, 851-857.	5.1	20
50	Inhibition of the Association with Nuclear Matrix of pRB, p70 and p40 Proteins Along with the Specific Suppression of c-MYC Expression by Geldanamycin, an Inhibitor of Src Tyrosine Kinase. <i>Journal of Antibiotics</i> , 1995, 48, 1021-1026.	2.0	20
51	Functional Involvement of PTP-U2L in Apoptosis Subsequent to Terminal Differentiation of Monoblastoid Leukemia Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 21187-21193.	3.4	20
52	mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer. <i>Oncotarget</i> , 2017, 8, 47902-47915.	1.8	20
53	Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation. <i>Cancer Science</i> , 2015, 106, 909-920.	3.9	18
54	Development of G-quadruplex ligands for selective induction of a parallel-type topology. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 7375-7382.	2.8	18

#	ARTICLE	IF	CITATIONS
55	Cell-based chemical fingerprinting identifies telomeres and lamin A as modifiers of DNA damage response in cancer cells. <i>Scientific Reports</i> , 2018, 8, 14827.	3.3	17
56	Target identification of a macrocyclic hexaoxazole G-quadruplex ligand using post-target-binding visualization. <i>Chemical Communications</i> , 2020, 56, 12905-12908.	4.1	17
57	2-deoxyglucose inhibits chemotheapeutic drug-induced apoptosis in human monocytic leukemia U937 cells ith inhibition of c-Jun N-terminal kinase 1/stress-activated protein kinase activation. , 1998, 76, 86-90.		16
58	Expression of Mutant RPA in Human Cancer Cells Causes Telomere Shortening. <i>Bioscience, Biotechnology and Biochemistry</i> , 2010, 74, 382-385.	1.3	16
59	MERIT40-dependent recruitment of tankyrase to damaged DNA and its implication for cell sensitivity to DNA-damaging anticancer drugs. <i>Oncotarget</i> , 2018, 9, 35844-35855.	1.8	15
60	Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 765-776.	4.1	14
61	Fission Yeast Pot1 and RecQ Helicase Are Required for Efficient Chromosome Segregation. <i>Molecular and Cellular Biology</i> , 2011, 31, 495-506.	2.3	13
62	In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells. <i>British Journal of Cancer</i> , 2019, 121, 846-856.	6.4	13
63	Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor. <i>Cancer Science</i> , 2021, 112, 1963-1974.	3.9	13
64	Mouseâ€Human Chimeric Antibody MH171 against the Multidrug Transporter Pâ€Glycoprotein. <i>Japanese Journal of Cancer Research</i> , 1992, 83, 515-521.	1.7	11
65	Calpain-10 regulates actin dynamics by proteolysis of microtubule-associated protein 1B. <i>Scientific Reports</i> , 2018, 8, 16756.	3.3	10
66	A fully synthetic 6-aza-artemisinin bearing an amphiphilic chain generates aggregates and exhibits anti-cancer activities. <i>Organic and Biomolecular Chemistry</i> , 2020, 18, 5339-5343.	2.8	10
67	Câ€quadruplexâ€forming nucleic acids interact with splicing factor 3B subunit 2 and suppress innate immune gene expression. <i>Genes To Cells</i> , 2021, 26, 65-82.	1.2	10
68	Chemical targeting of G-quadruplexes in telomeres and beyond for molecular cancer therapeutics. <i>Journal of Antibiotics</i> , 2021, 74, 617-628.	2.0	10
69	Telomere elongation by a mutant tankyrase 1 without TRF1 poly(ADP-ribosyl)ation. <i>Experimental Cell Research</i> , 2008, 314, 1115-1124.	2.6	9
70	Development of a gene expression database and related analysis programs for evaluation of anticancer compounds. <i>Cancer Science</i> , 2013, 104, 360-368.	3.9	9
71	Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. <i>Cancer Science</i> , 2020, 111, 441-450.	3.9	8
72	Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo. <i>Scientific Reports</i> , 2021, 11, 15125.	3.3	8

#	ARTICLE	IF	CITATIONS
73	Interaction of long telomeric DNAs with macrocyclic hexaoxazole as a G-quadruplex ligand. <i>MedChemComm</i> , 2013, 4, 260-264.	3.4	7
74	Evaluation of Tankyrase Inhibition in Whole Cells. <i>Methods in Molecular Biology</i> , 2007, 405, 133-146.	0.9	7
75	c-KIT regulates stability of cancer stemness in CD44-positive colorectal cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2020, 527, 1014-1020.	2.1	7
76	Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. <i>Cancer Science</i> , 2016, 107, 189-202.	3.9	6
77	A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. <i>Investigational New Drugs</i> , 2020, 38, 111-119.	2.6	6
78	Apoptosis resistance in tumor cells. <i>Cytotechnology</i> , 1998, 27, 293-308.	1.6	5
79	JBIR-120: a new growth inhibitor of hormone-refractory prostate cancer cells. <i>Journal of Antibiotics</i> , 2012, 65, 373-375.	2.0	5
80	T Cell Receptor-Extracellular Constant Regions as Hetero-Cross-Linkers for Immunoglobulin Variable Regions. <i>Journal of Biochemistry</i> , 1993, 113, 687-691.	1.7	4
81	Tankyrase assembly to large protein complexes blocks its telomeric function. <i>FEBS Letters</i> , 2010, 584, 3885-3890.	2.8	4
82	Predicting Risk at the End of the End: Telomere G-tail as a Biomarker. <i>EBioMedicine</i> , 2015, 2, 804-805.	6.1	4
83	Novel tankyrase inhibitors suppress TDP-43 aggregate formation. <i>Biochemical and Biophysical Research Communications</i> , 2021, 537, 85-92.	2.1	4
84	Role of EMT in the DNA damage response, double-strand break repair pathway choice and its implications in cancer treatment. <i>Cancer Science</i> , 2022, , .	3.9	4
85	Design, Synthesis and Evaluation of an L-Dopa-Derived Macrocyclic Hexaoxazole (6otd) as a G-Quadruplex-Selective Ligand. <i>Heterocycles</i> , 2016, 92, 305.	0.7	3
86	From the wings to the center stage of chromosomes. <i>Journal of Biological Chemistry</i> , 2019, 294, 17723-17724.	3.4	3
87	Tankyrase promotes primary precursor miRNA processing to precursor miRNA. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 945-951.	2.1	3
88	Design and synthesis of 14 and 15-membered macrocyclic scaffolds exhibiting inhibitory activities of hypoxia-inducible factor 1 α . <i>Bioorganic and Medicinal Chemistry</i> , 2021, 30, 115949.	3.0	3
89	Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2021, 36, 131-139.	2.2	3
90	Cancer therapy targeting the telomere maintenance system. <i>Drug Delivery System</i> , 2006, 21, 24-31.	0.0	2

#	ARTICLE	IF	CITATIONS
91	ãfťãfãfjã,¢ãf»ãfťãfãfjãf-ãf¼ã,1ã,æ™çš,,ã*ã-ãŸæš—è...«ç̃™,æ³•. Kagaku To Seibutsu, 2010, 48, 713-719. o.o		0
92	Fission Yeast Pot1 and RecQ Helicase Are Required for Efficient Chromosome Segregation. Molecular and Cellular Biology, 2014, 34, 2551-2552.	2.3	0
93	Recent advances in telomere biology for new cancer medicine. Annals of Oncology, 2016, 27, vii70.	1.2	0
94	Therapeutic Targets and Drugs III: Tankyrase 1, Telomere-Binding Proteins, and Inhibitors. , 2009, , 281-291.		0
95	Role of Acyl-CoA Synthetases in Glioma Cell Survival and Its Therapeutic Implication. , 2011, , 337-340.		0
96	Tankyrases. , 2011, , 3604-3606.		0
97	Tankyrases. , 2014, , 1-4.		0
98	Apoptosis resistance in tumor cells. , 1998, , 293-308.		0
99	Tankyrases. , 2017, , 4446-4449.		0